A high-throughput kinome screen reveals serum/glucocorticoidregulated kinase 1 as a therapeutic target for NF2-deficient meningiomas

Oncotarget

Volumn 6, Issue 19, 2015, Pages 16981-16997

  Beauchamp, Roberta L ^a   James, Marianne F ^a   DeSouza, Patrick A ^a   Wagh, Vilas ^a   Zhao, Wen Ning ^a   Jordan, Justin T ^a   Stemmer Rachamimov, Anat ^a   Plotkin, Scott R ^a   Gusella, James F ^a   Haggarty, Stephen J ^a   Ramesh, Vijaya ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AZD2014; Meningioma; mTOR signaling; NF2; SGK1

Indexed keywords

AZD 2014; CASPASE 9; FRAX 597; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MERLIN; P21 ACTIVATED KINASE 1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAC1 PROTEIN; RAPAMYCIN; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMEDIATE EARLY PROTEIN; MORPHOLINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE; VISTUSERTIB;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MENINGIOMA; NERVE CELL; PROTEIN EXPRESSION; PROTEIN TARGETING; DRUG EFFECTS; ENZYMOLOGY; GENE SILENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOBLOTTING; METABOLISM; NEUROFIBROMATOSIS TYPE 2; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOBLOTTING; MENINGEAL NEOPLASMS; MENINGIOMA; MORPHOLINES; NEUROFIBROMATOSIS 2; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84938230839     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4858     Document Type: Article

References (52)

1. Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med. 2009; 11:599-610.
2. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, Delattre O, Thomas G, Nordenskjold M, Collins VP, Dumanski JP and Rouleau GA. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994; 6:180-184.
3. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M and Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005; 57:1088-1095.
4. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC and Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61:215-225.
5. Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012; 158A:24-41.
6. McClatchey AI and Fehon RG. Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 2009; 19:198-206.
7. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF and Ramesh V. NF2/Merlin is a Novel Negative Regulator of mTOR Complex 1 and Activation of mTORC1 is Associated with Meningioma and Schwannoma Growth. Mol Cell Biol. 2009; 29:4250-4261.
8. James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V and Gusella JF. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008; 29:278-292.
9. Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E and Mawrin C. mTORC1 inhibitors suppress meningioma growth in mouse models. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013; 19:1180-1189.
10. Giovannini M, Bonne NX, Vitte J, Chareyre F, Tanaka K, Adams R, Fisher LM, Valeyrie-Allanore L, Wolkenstein P, Goutagny S and Kalamarides M. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol. 2014; 16:493-504.
11. Karajannis MA, Legault G, Hagiwara M, Giancotti FG, Filatov A, Derman A, Hochman T, Goldberg JD, Vega E, Wisoff JH, Golfinos JG, Merkelson A, Roland JT and Allen JC. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2014; 16:292-297.
12. Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D, Larroque B, Sterkers O, Giovannini M and Kalamarides M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. Journal of neuro-oncology. 2015; 122:313-320.
13. Betz C and Hall MN. Where is mTOR and what is it doing there? The Journal of cell biology. 2013; 203:563-574.
14. Guertin DA and Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12:9-22.
15. Puttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH and Paulus W. Establishment of a benign meningioma cell line by hTERT-mediated immortalization. Lab Invest. 2005; 85:1163-1171.
16. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P and Shamu CE. Statistical methods for analysis of highthroughput RNA interference screens. Nature methods. 2009; 6:569-575.
17. Garcia-Martinez JM and Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). The Biochemical journal. 2008; 416:375-385.
18. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6:729-734.
19. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science. 2005; 307:1098-1101.
20. Huang J, Wu S, Wu CL and Manning BD. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 2009; 69:6107-6114.
21. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, Gusella JF, Stemmer-Rachamimov AO and Ramesh V. Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types. Mol Cancer Res. 2012; 10:649-659.
22. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB and Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 2003; 12:841-849.
23. Xiao GH, Beeser A, Chernoff J and Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. Journal of Biological Chemistry. 2002; 277:883-886.
24. Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A and Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res. 2008; 68:7932-7937.
25. Chow HY, Dong B, Duron SG, Campbell DA, Ong CC, Hoeflich KP, Chang LS, Welling DB, Yang ZJ and Chernoff J. Group I Paks as therapeutic targets in NF2- deficient meningioma. Oncotarget. 2015; 6:1981-1994.
26. Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S, Campbell D, Chernoff J, Field J, Marmorstein R and Kissil JL. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. The Journal of biological chemistry. 2013; 288:29105-29114.
27. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R and Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell. 2008; 30:701-711.
28. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG and Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014; 343:84-87.
29. Loffing J, Flores SY and Staub O. Sgk kinases and their role in epithelial transport. Annu Rev Physiol. 2006; 68:461-490.
30. Lang F and Stournaras C. Serum and glucocorticoid inducible kinase, metabolic syndrome, inflammation, and tumor growth. Hormones (Athens). 2013; 12:160-171.
31. Sahoo S, Brickley DR, Kocherginsky M and Conzen SD. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur J Cancer. 2005; 41:2754-2759.
32. Guertin DA and Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2:pe24.
33. Lopez-Lago MA, Okada T, Murillo MM, Socci N and Giancotti FG. Loss of the Tumor Suppressor NF2/Merlin Constitutively Activates Integrin-dependent mTORC1 Signaling. Mol Cell Biol. 2009; 29:4235-4249.
34. Liu Y, Shoji-Kawata S, Sumpter RM, Jr., Wei Y, Ginet V, Zhang L, Posner B, Tran KA, Green DR, Xavier RJ, Shaw SY, Clarke PG, Puyal J and Levine B. Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxiaischemia. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:20364-20371.
35. Pearce LR, Komander D and Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010; 11:9-22.
36. Bruhn MA, Pearson RB, Hannan RD and Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth Factors. 2010; 28:394-408.
37. Brunet A, Park J, Tran H, Hu LS, Hemmings BA and Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Molecular and cellular biology. 2001; 21:952-965.
38. Sommer EM, Dry H, Cross D, Guichard S, Davies BR and Alessi DR. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. The Biochemical journal. 2013; 452:499-508.
39. Huang J and Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009; 37:217-222.
40. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, et al. Oncogenic EGFR signaling activates an mTORC2-NFkappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011; 1:524-538.
41. Lallemand D, Curto M, Saotome I, Giovannini M and McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 2003; 17:1090-1100.
42. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, Lampin A, Niwa-Kawakita M, Kalamarides M and Giovannini M. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene. 2009; 28:854-865.
43. Lu M, Wang J, Ives HE and Pearce D. mSIN1 protein mediates SGK1 protein interaction with mTORC2 protein complex and is required for selective activation of the epithelial sodium channel. The Journal of biological chemistry. 2011; 286:30647-30654.
44. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH and Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 2002; 16:1060-1065.
45. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP and Lamb RF. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004; 166:213-223.
46. Shah OJ, Wang Z and Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol. 2004; 14:1650-1656.
47. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA and Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332:1317-1322.
48. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP and Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332:1322-1326.
49. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, Yuan M, Kim BM, Shaik S, Menon S, Gygi SP, Lee TH, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nature cell biology. 2013; 15:1340-1350.
50. Luo Y, Liu L, Wu Y, Singh K, Su B, Zhang N, Liu X, Shen Y and Huang S. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2. Oncotarget. 2015; 6:4286-4298.
51. Basu B, Dean E, Puglisi M, Greystroke A, Ong M, Burke WM, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson MR and Banerji U. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. Clinical cancer research. 2015; [Epub ahead of print].
52. Wiederhold T, Lee MF, James M, Neujahr R, Smith N, Murthy A, Hartwig J, Gusella JF and Ramesh V. Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2. Oncogene. 2004; 23:8815-8825.